GlassScriptPhysician profile
James Walter Steves
NPI 1518232818
$1,748.88
in general payments reported to CMS, 2019-2025
21 companies · $656 in 2025
The $656 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $437 · 2023: $215 · 2024: $440 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,311.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $314.56 | 2024-2025 | Airsupra, Fasenra, Tezspire |
| Abiomed | $293.33 | 2022 | |
| Glaxosmithkline, LLC. | $282.02 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $126.98 | 2022-2025 | |
| Verona Pharma, INC. | $98.63 | 2025 | Ohtuvayre |
| Regeneron Healthcare Solutions, INC. | $93.97 | 2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $82.56 | 2024 | Glassia |
| Viatris Specialty LLC | $72.16 | 2025 | Yupelri |
| Electromed, INC. | $63.12 | 2024 | Smartvest |
| Philips North America LLC | $55.14 | 2022 | |
| Janssen Pharmaceuticals, INC | $39.69 | 2024 | Xarelto |
| Tactile Systems Technology INC | $33.29 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Actelion Pharmaceuticals US, INC. | $30.68 | 2023 | Opsumit |
| Amgen INC. | $28.60 | 2025 | Tezspire |
| Paratek Pharmaceuticals, INC. | $23.20 | 2023 | Nuzyra |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $21.49 | 2024 | Yupelri |
| Baxter Healthcare | $21.28 | 2022 | |
| United Therapeutics Corporation | $20.73 | 2025 | Tyvaso |
| Mallinckrodt Hospital Products INC. | $20.66 | 2025 | Acthar |
| Gilead Sciences, INC. | $14.07 | 2023 | Veklury |
| Pulmonx Corporation | $12.72 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Steves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.